- 2.7Impact Factor
- 4.5CiteScore
- 23 daysTime to First Decision
Antibody-Drug Conjugates
Special Issue Information
Dear Colleagues,
Antibody-drug conjugates (ADC) represent an innovative therapeutic application that combines the exquisite properties of monoclonal antibodies, with the potent cell killing activity of cytotoxic small molecule drugs, thus reducing systemic toxicity (often seen with small molecule drugs) while increasing the therapeutic benefits for patients. A special issue of Antibodies, with focus on ADC, welcome manuscripts with examples of early and recent ADC, focusing on choosing the right target, choosing the right antibody, choosing the right cytotoxic small molecule warhead, choosing the right linker, choosing the right site of conjugation on the antibody or antibody fragment, and finally putting the ADC all together. Moreover, manuscript describing novel bio-conjugation strategies, methods to stabilize the ADC, toxicities related to ADC and ADC efficacy in both pre- and clinical settings are also welcome.
Dr. Nazzareno Dimasi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody-drug conjugates
- small-molecule drugs/warheads
- macromolecule toxins/immunotoxins
- bio-conjugation/antibody modification
- cysteine- and lysine-mediated conjugation
- multifunctional bio-conjugation
- tumor targets/receptors internalization
- site-specific antibody conjugation
- maleimide-based conjugation/maleimide modifications
- stabilized maleimides
- biofunctional linkers
- armed antibodies
- homogeneous conjugation
- cleavable and un-cleavable linkers
- toxicities as relate to antibody-drug conjugates
- efficacy of antibody-drug conjugates
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

